Press Releases

Date	Description	View
Feb 15, 2019	Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease
Jan 08, 2019	Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS
Dec 10, 2018	Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson's Disease
Nov 19, 2018	Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
Nov 08, 2018	Denali Therapeutics Reports Third Quarter 2018 Financial Results And Business Highlights And Announces The Appointment Of Jennifer Cook To Board Of Directors
Oct 31, 2018	Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases
Oct 03, 2018	CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials
Aug 09, 2018	Denali Therapeutics Reports Second Quarter 2018 Financial Results
Aug 07, 2018	Denali Therapeutics Appoints Dana Andersen, Ph.D., As Chief Technical And Manufacturing Officer
Aug 01, 2018	Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson’s Disease
May 30, 2018	Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-Star Gamma
May 11, 2018	Denali Therapeutics Reports First Quarter 2018 Financial Results
Mar 19, 2018	Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
Feb 08, 2018	Denali Therapeutics And Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines
Jan 05, 2018	Takeda And Denali Therapeutics Collaborate To Develop And Commercialize Therapies For Neurodegenerative Diseases
Dec 20, 2017	Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’s Disease
Dec 12, 2017	Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares
Dec 07, 2017	Denali Therapeutics Announces Pricing Of Initial Public Offering
Aug 25, 2016	Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B
Sep 08, 2015	Denali Therapeutics Appoints Steve E. Krognes As Chief Financial Officer
Jul 22, 2015	Denali Therapeutics Appoints Carole Ho, M.D., As Chief Medical Officer And Head Of Development
May 14, 2015	Denali Therapeutics Launches With Initial Investment To Discover And Develop Treatments For Neurodegenerative Diseases